◆
Precision skin & connective tissue matrix formula: GHK-Cu, BPC-157, and TB-500.
Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Research Dose Reference
Multi-compound blend vial
GLOW BLEND
Skin & Hair
Research dose range
0 mcg250 mcg500 mcg750 mcg1000 mcg
Standard research range
500 - 750 mcg
Core experimental protocol for active dermal remodeling and microvascular support.
Research focus
Connective tissue & dermal matrix regeneration
Observed window
6-12 weeks
Administration
Daily or alternate-day laboratory administration
Primary pathway
VEGF / Collagen I & III / Actin cytoskeleton remodeling
Dosing extrapolation based on individual constituent peptide literature. Strictly for in-vitro and laboratory research use.
PROTOCOL BENEFITS
Engineered Outcomes
Triple Peptide MatrixDermal RemodelingCollagen & Angiogenesis
◆
Simultaneously promotes microvascular angiogenesis, fibroblast migration, and pro-collagen synthesis.
◆
Engineered to support comprehensive extracellular matrix repair and dermal rejuvenation.
SCIENCE
How It Works.
GLOW Blend unites three benchmark peptides into a unified cellular regeneration solution: GHK-Cu (copper tripeptide), BPC-157 (pentadecapeptide), and TB-500 (thymosin beta-4 fragment). Together, they address connective tissue remodeling across three separate biological tiers.
GHK-Cu stimulates dermal fibroblast migration and collagen type I/III synthesis; BPC-157 upregulates VEGF and early growth response-1 (egr-1) for vascularization; and TB-500 sequesters G-actin to enable rapid cellular motility across injured tissue matrices.
WHAT TO EXPECT
Localized tissue hydration and anti-inflammatory markers respond within 1–2 weeks, while structural dermal collagen density changes are tracked across 6–12 week observation windows.
PROTOCOL NOTE
Available in combined multi-peptide research vials. Strictly for laboratory research.
FAQ
Protocol Questions
What is the difference between GLOW and KLOW?+
GLOW combines GHK-Cu, BPC-157, and TB-500 for skin and tissue remodeling. KLOW uses the same core formulation with the addition of KPV to target active inflammatory cascades.
Does the 5:1:1 ratio equal administering each peptide separately?+
Not necessarily. GLOW provides fixed proportions (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500), whereas separate vials permit independent titration of each constituent compound.